Abstract
Plasmid-launched live-attenuated vaccines (PLLAV) are a modality of next-generation vaccines with the promise to combine the benefits of both (1) the potency of live vaccines and (2) the ease of production, quality control, and thermal stability of classical DNA vaccines. Using the live yellow fever 17D (YF17D) vaccine as paradigm, we establish a bioluminescence-based in vivo imaging approach that allows to rapidly monitor and optimize the dose and route of delivery of such PLLAV in a mouse model of YF17D immunization. Vaccine virus replication thus launched in the skin of vaccinated mice can be quantified by the light emitted, benchmarked to signals originating from a YF17D reporter virus and finally correlated to the induction of humoral immune responses to the yellow fever virus.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pulendran B et al (2013) Immunity to viruses: learning from successful human vaccines. Immunol Rev 255(1):243–255
Draper SJ, Heeney JL (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8(1):62–73
Pushko P et al (2016) DNA-launched live-attenuated vaccines for biodefense applications. Expert Rev Vaccines 15(9):1223–1234
Aubrit F et al (2015) Cell substrates for the production of viral vaccines. Vaccine 33(44):5905–5912
Rodrigues AF et al (2015) Viral vaccines and their manufacturing cell substrates: new trends and designs in modern vaccinology. Biotechnol J 10(9):1329–1344
Tretyakova I et al (2019) Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome. Vaccine 37(25):3317–3325
Jiang X et al (2015) Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone. J Gen Virol 96(Pt 4):804–814
Kum DB et al (2019) Limited evolution of the yellow fever virus 17d in a mouse infection model. Emerg Microbes Infect 8(1):1734–1746
Kupper TS, Fuhlbrigge RC (2004) Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 4(3):211–222
Nagao K et al (2009) Murine epidermal Langerhans cells and langerin-expressing dermal dendritic cells are unrelated and exhibit distinct functions. Proc Natl Acad Sci U S A 106(9):3312–3317
Roukens AH et al (2008) Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS One 3(4):e1993
Young F, Marra F (2011) A systematic review of intradermal influenza vaccines. Vaccine 29(48):8788–8801
Rosa DS et al (2015) Multiple approaches for increasing the immunogenicity of an epitope-based anti-HIV vaccine. AIDS Res Hum Retrovir 31(11):1077–1088
Zhang L et al (2008) T cell epitope-based peptide-DNA dual vaccine induces protective immunity against Schistosoma japonicum infection in C57BL/6J mice. Microbes Infect 10(3):251–259
Yang ZY et al (2004) A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428(6982):561–564
Lee LYY, Izzard L, Hurt AC (2018) A review of DNA vaccines against influenza. Front Immunol 9:1568
Li L, Petrovsky N (2016) Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines 15(3):313–329
Zhu Y et al (2003) Protective immunity induced with 23 kDa membrane protein dna vaccine of Schistosoma japonicum Chinese strain in infected C57BL/6 mice. Southeast Asian J Trop Med Public Health 34(4):697–701
Avci P et al (2018) In-vivo monitoring of infectious diseases in living animals using bioluminescence imaging. Virulence 9(1):28–63
Sharma S et al (2020) Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine. Hum Vaccin Immunother 16(9):2196–2203
Mishra N et al (2020) A Chimeric Japanese encephalitis vaccine protects against lethal yellow fever virus infection without inducing neutralizing antibodies. mBio 11(2):e02494-19
Kum DB et al (2020) A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice. Emerg Microbes Infect 9(1):520–533
Acknowledgments
The authors acknowledge funding by the Flemish Research Foundation (FWO) Excellence of Science (EOS) program (No. 30981113; VirEOS project), the European Union’s Horizon 2020 research and innovation program (No 733176; RABYD-VAX consortium), the Bill and Melinda Gates Foundation (OPP1195179), and KU Leuven Internal Funds (C3/19/059; Lab of Excellence and IDN/20/011; MIRACLE).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Sharma, S., Dallmeier, K. (2022). Use of Optical In Vivo Imaging to Monitor and Optimize Delivery of Novel Plasmid-Launched Live-Attenuated Vaccines. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 2412. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1892-9_14
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1892-9_14
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1891-2
Online ISBN: 978-1-0716-1892-9
eBook Packages: Springer Protocols